Excellent points.
(Full disclosure- I am waiting for
Excellent points.
(Full disclosure- I am waiting for the full picture before determining which way to land on this. And - even though they are huge to me- not enough shares for my vote to mean anything to anybody but me.)
Stockholder letter today was the first bit of straight-from-the-horse's mouth information I have had to be able to evaluate the 5% group that was not based on hearsay. Two things were striking:
1) Point #2- Letter insinuates that 'based on a poor and unsalvageable relationship' caused Dr. Pourhassan and Dr. Kelly, the FDA has repeatedly 'refused to authorize CYDY-led clinical trials or even authorize applications' for leron.
I retired from the government public health sector- and this blew my mind-- on many levels. What does this mean to a government worker? Are they stating- on paper- that government workers are highly influenced by their relationships? that the approval of leron has been based on how much people like each other? - that the 'relationship; is the big criteria used to evaluate and process drug approval? A government employee with integrity will not take this accusation well. -If you are one that believes no one/ no government employee has integrity- OK- even then they will not like it being insinuated in a public document- especially with the hot water FDA is in now.
2) "Their priorities are clear: enrich themselves first, worry about the Company and generating value for stockholders last."
OK- what in your plan is going to hold any of the proposed new BOD to a different standard? How are the 5%'s going to limit the BOD compensation? I would be all ears to hear the ways they will limit lining their pockets- very much including selling it out and their involvement with IncellDx and BP. Certainly won't assume the worst - but for full disclosure.
Anywho- lots to figure out- for me anyway.
GLTA- CGC
13
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Market Momentum and Emerging Trends in AI and Privacy Tokens Recently, the global crypto market found itself amidst a wave of activity, highlighted by the resurgence of the AI and privacy sectors. Despite facing volatility, these niche markets have captured the attention of investors and traders, resulting in vibrant trading on platforms like HTX. This surge reflects not...
Continue Reading
Banzai Welcomes New Chief Financial Officer Banzai International, Inc. (NASDAQ: BNZI), a prominent player in marketing technology, has announced the exciting appointment of Dean Ditto as its new Chief Financial Officer. This strategic move, which marks a significant development in the company’s management, is aimed at enhancing its financial operations and overall...
Continue Reading
Cybin Inc. Announces Share Consolidation Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN), a key player in neuropsychiatry focused on innovative treatments, has taken a significant step by consolidating its common shares. Starting immediately, every 38 existing shares have been combined into a single new share, which notably decreases the total number of shares available....
Continue Reading
Voreifarem Partners with SwfcNrho Exchange In an exciting development for the digital health sector, Voreifarem has officially launched its trading on the popular compliant platform, SwfcNrho. Known for being the first digital health project utilizing the combination of medical chips and blockchain technology, Voreifarem is making waves with its token IER. This recent...
Continue Reading
ez1095 ACA Software 2025: Enhance Your Filing Experience The latest ez1095 software from Halfpricesoft.com includes a cutting-edge network edition that enables organizations to file ACA forms to the IRS from multiple locations. This feature is especially vital as companies continue to embrace remote work and flexible operational structures. Key Features of ez1095 Software...
Continue Reading
